DGAP-News

Evotec receives first milestone in Roche biomarker collaboration

DGAP-News: Evotec AG / Key word(s): Miscellaneous
Evotec receives first milestone in Roche biomarker collaboration

24.04.2014 / 07:29

---------------------------------------------------------------------

Hamburg, Germany - 24 April 2014: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX, ISIN: DE0005664809) today announced the successful achievement of a
milestone in its biomarker alliance with Roche. The milestone was achieved
on the decision by Roche to use a response prediction marker, identified
using Evotec's Proteome Profiling platform, in an extended phase I oncology
trial.

This is the first minor milestone achieved under the collaboration and
licence agreement between Evotec and Roche, signed in 2011, which is part
of the m4 Munich Biotech Cluster Personalized Medicine and Targeted
Therapies initiative funded by the German Federal Ministry of Education and
Research. Under the initial three-year term, Evotec and Roche conduct
biomarker discovery and validation programmes for patient stratification in
targeted cancer therapy. Evotec is eligible for further success-based
payments upon clinical companion diagnostics development.

Dr Mario Polywka, Chief Operating Officer of Evotec AG, commented: "We are
delighted with receiving this milestone and the first validation of our
novel biomarker concept with Roche. I would like to thank everyone involved
in the project to date for the fantastic science they have developed and
for the hard work and determination to see it succeed in a clinical
setting."

About the Proteome Profiling platform
Evotec's Proteome Profiling platform employs high-end mass spectrometry to
identify and quantify thousands of cellular proteins on a global scale.
Unlike immunoassays, Proteome Profiling allows truly unbiased systems-wide
investigation of protein expression in vivo. Comparative analysis of
cellular proteomes not only supports target identification and
mode-of-action studies but also enables the discovery of predictive
biomarkers on the functional protein level.


ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience